Abstract
This pictorial review is based on our experience of the follow-up of 120 patients at our multidisciplinary center for hereditary hemorrhagic telangiectasia (HHT). Rendu-Osler-Weber disease or HHT is a multiorgan autosomal dominant disorder with high penetrance, characterized by epistaxis, mucocutaneous telangiectasis, and visceral arteriovenous malformations (AVMs). The research on gene mutations is fundamental and family screening by clinical examination, chest X-ray, research of pulmonary shunting, and abdominal color Doppler sonography is absolutely necessary. The angioarchitecture of pulmonary AVMs can be studied by unenhanced multidetector computed tomography; however, all other explorations of liver, digestive bowels, or brain require administration of contrast media. Magnetic resonance angiography is helpful for central nervous system screening, in particular for the spinal cord, but also for pulmonary, hepatic, and pelvic AVMs. Knowledge of the multiorgan involvement of HHT, mechanism of complications, and radiologic findings is fundamental for the correct management of these patients.
Similar content being viewed by others
Explore related subjects
Find the latest articles, discoveries, and news in related topics.Avoid common mistakes on your manuscript.
Introduction
Hereditary hemorrhagic telangiectasia (HHT), or Rendu-Osler-Weber disease, is an autosomal dominant multiorgan pathology with a prevalence of 1 in 10,000 to 1 in 5000 [1] and characterized by the presence of multiple small telangiectases of the skin, mucous membranes, gastrointestinal tract, and other organs, with associated recurrent episodes of bleeding from affected sites. Although everyday symptoms in these patients are dominated by epistaxis that may markedly alter their quality of life, more severe manifestations of the disease are due to the consequences of pulmonary arteriovenous malformations (PAVMs) and, less often, to liver, brain, or gastrointestinal tract involvement [1]. The diagnosis of HHT requires the presence of at least three of the following Curacao criteria: recurrent spontaneous epistaxis, mucocutaneous telangiectasis, an autosomal dominant familial distribution of the disease, and visceral AVMs.
The mutations of the endoglin gene (ENG) on the 9q chromosome and the aktivine gene (ALK1) on the 12q chromosome are implicated in the inheritance of this disease [2]. Furthermore, the ENG mutations determine the HHT1 disease subtype, which correlates with a more critical pulmonary involvement, and AKL1 mutations indicate the HHT2 subtype, with a predominance of liver involvement [2].
The purpose of this article is to provide a brief review of the visceral involvement and the relevant findings on diagnostic and therapeutic imaging.
Lung
PAVM is the most frequent lesion of the lung in patients with HHT. It occurs in 20% to 50% and provokes different clinical symptoms, such as dyspnea, cyanosis, massive hemoptysis, and hemothorax [1]. The shunt induces various paradoxical emboli such as cruoric, bacterial, and gaseous [1]. Currently, it is known that for clinical relevance, the diameter of the artery of the PAVM must be ≥3 mm. However, one case with a feeding artery diameter <3 mm (Fig. 1) and responsible for ischemic stroke has been reported [3].
The anatomic structure of the PAVM is classified according to the two types [4] defined as simple, with a single artery feeding into an aneurysmal communication with a single draining vein (Fig. 2, Movies 1 and 2), and complex, with two or more arterial branches communicating via an aneurysm with two or more draining veins (Fig. 3). On chest X-ray, a PAVM classically appears as a well-defined nodule with a minimum of two branching vessels (Fig. 4A). However, chest X-ray, although rather specific, is not sensitive [5]. Diagnosis is performed on unenhanced helical CT with a small slab of maximum intensity projection reconstruction showing one or more enlarged arteries, feeding a serpiginous mass or nodule, and one or more draining veins (Fig. 4B and C) [5]. Contrast-enhanced magnetic resonance angiography (CE-MRA) shows clearly all PAVMs (Fig. 4D) whose feeding arteries are larger than 3 mm [6]. Because PAVMs have predilections for affecting the lower lobes, exploration of the pleural sac is fundamental (Fig. 5A). Pulmonary angiography, which is an invasive procedure, less effective than chest CT, is no longer used for diagnostic purposes and its use is restricted to treatment. Transarterial PAVM vaso-occlusion with coils (Fig. 5B and C) is currently the treatment of choice [1]. Because of possible reperfusion more than the development of small PAVMs due to redistribution of the hemodynamic flow after transcatheter occlusion of large PAVMs, a CT or CE-MRA follow-up (Fig. 6A and B) is recommended [6]. Reperfusion of occluded PAVMs occurs in as many as 19% [7] of them after initially successful treatment (Fig. 7A); the flux through the coils is better seen on CE-MRA (Fig. 7B) and is confirmed during the new vaso-occlusion procedure (Fig. 7C). Reperfusion risk increases with increasing PAVM feeding artery diameter, the use of a small number of coils (one or two) [8] (Fig. 8) or oversized coils, and coil placement proximally within the feeding artery. When reperfusion appears, the patient remains at risk for complications, so a new embolization must be performed [9]. When the cause is too proximal coil placement, the reperfusion can be due to a hypertrophy of a bronchial or systemic artery [10]; such a reperfusion does not cause shunting but can be responsible for hemoptysis.
Brain
The mechanisms of central nervous system (CNS) involvement in HHT are distal emboli, cerebrovascular malformation (CVM), and metabolic disorders [2, 11]. PAVM shunting that avoids the filtering effect of pulmonary capillaries is the most frequent mechanism inducing cerebral embolism and subsequent stroke (Fig. 9) or brain abscess secondary to cruoric and septic emboli, respectively (Fig. 10A). Furthermore, polycythemia secondary to chronic hypoxemia favors in situ formation of a cruoric embolus [1]. Multiple ischemic strokes in different arterial territories at different ages characterize the embolic mechanism in HHT (Fig. 9). Brain abscess is the most serious neurologic complication, occurring in 5% to 10% of patients with PAVM. Typically in HHT these abscesses are multiple and recurrent, affecting the superficial layers of the cerebral lobes (mostly the parietal lobe) and developing often between the third and the fifth decade of life, when PAVMs increase in size and number. Transarterial PAVM vaso-occlusion is a key procedure to prevent these cerebral complications in HHT.
Spinal and cerebral vascular malformations are manifestations of underlying vascular dysplasia [12]. These lesions represent abnormal arteriovenous connections that failed to differentiate properly into arteriolar, capillary, and venular channels [13]. On magnetic resonance imaging (MRI), CVMs appear as areas of serpiginous flow voids insinuating into the brain parenchyma (Fig. 11). Patients with HHT often have multiple malformations of various types, some of them with an atypical or indeterminate MRI appearance [14]. Cerebral angiography may be required for diagnosis of equivocal lesions and for planning of treatment. The therapy for symptomatic CVMs is surgical resection, stereotactic radiosurgery, embolization, or a combination of these treatments [15].
Finally, the T1-weighted image hyperintensity of the basal nuclei correlates with a metabolic disorder related to hepatic portal vein shunt [16].
Liver
Hepatic involvement occurs in 30% to 73% of patients with HHT; most of them are asymptomatic or have a slight elevation of γ-glutamyltransferase (GGT) but rare complications occur, especially in female patients [11, 17].
Three different and often concurrent types of intrahepatic shunts (hepatic artery to hepatic veins, hepatic artery to portal vein, and portal vein to hepatic veins) are responsible for the parenchymal, vascular, and bile duct signs [11]. Hepatic abnormalities are diagnosed by Doppler ultrasound, MDCT, MRI, and MRA. Hepatic ultrasound associated with Doppler is a good tool with an experienced investigator [18]; otherwise findings can be considered as normal in the early stage because telangiectases are difficult to diagnose. The diameter of the common hepatic artery (>7 mm; Fig. 12A) and intrahepatic hypervascularization are suitable sonographic diagnostic parameters of HHT with a high sensitivity and specificity [18]. Rarely, Doppler ultrasound can reveal pulsatile portal flow (arterioportal shunt; Fig. 12B) or pulsatile hepatic vein flow (arteriovenous shunt; Fig. 12C).
Hepatic vascular lesions on MDCT range from tiny telangiectases (Fig. 12D) to transient perfusion abnormalities and large confluent focal vascular masses [19]. These lesions are often associated with arteriovenous, arterioportal, or portovenous shunts and hepatic artery enlargement (Fig. 12E–G). Telengiectases are hypervascular rounded nodules (varying from a few millimeters to 1 cm in size) localized in a subcapsular position in the arterial and late arterial phases, often becoming isointense with the hepatic parenchyma in the hepatic parenchymal phase. Arteriography, too aggressive for a screening and diagnosis tool, could be the best method to characterize telangiectases.
The natural evolution of hepatic teangiectasia in MRO patients is toward intrahepatic vascular shunts [20]. If simple telangiectasis can rarely provoke a painful liver with a slight elevation of GGT, arteriovenous shunts are more communicative. An arterioportal shunt may rarely induce portal hypertension, ascites, encephalopathy, and hematemesis. An arteriovenous shunt can, on rare occasions, be responsible for high-output heart failure and necrotizing cholangitis by arterial flow steal (the arterial supply of the biliary duct is exclusively dependent on the hepatic artery) [20]. Livers in patients with HHT may show either diffuse or partial hepatocellular regenerative activity, leading to regenerative focal nodular hyperplasia (FNH; Fig. 13A–D). The prevalence of FNH in patients with HHT is 100-fold greater than in the general population and can lead to dangerous hepatic biopsies. The combination of fibrosis (around abnormal vessels), nodular regenerative hyperplasia, and portal hypertension may lead to a misdiagnosis of cirrhosis [11]. Occasionally, patients with HHT present with true cirrhosis (secondary to extensive necrotizing cholangitis), hepatocarcinoma, or hemobilia (secondary to a MAV rupture in the biliary system). Angiomas can also coexist with telangiectases and hepatic MAV. Rarely, pancreatic telangiectasis can be associated with liver lesions (Fig. 14).
Transarterial embolization of liver arteriovenous fistulas has been performed but fatal outcomes due to necrotizing cholangitis suggest caution in its use. Orthotopic liver transplantation may represent the only definitive curative option for hepatic vascular malformations in HHT, even though at this time relapse has been observed in 2 of 28 patients undergoing transplantation [17].
Gastrointestinal Tract
Recurrent upper or lower gastrointestinal bleeding occurs in approximately 20% of patients with HHT and is responsible for anemia. The risk of fatal bleeding is mostly due to intestinal mucosal telangiectasis predominating in the gastroduodenal region, and less, frequently to intestinal AV shunt or angiodysplasia. Classical imaging techniques are limited. Only large AV malformations can be diagnosed on CT scan. The technique of capsule endoscopy is emerging to study the small bowel. Endoscopy is the gold standard for diagnosis and therapy of gastroduodenal and colonic telangiectases [21].
Summary
In summary, knowledge of genetic findings and of phenotypes leads to optimal management of the patient and family. In these patients, diagnosis and adequate therapeutic choice, with a multidisciplinary approach, can prevent serious complications and avoid the need for hepatic biopsies in the case of hepatic involvement.
References
Cottin V, Chinet T, Lavole A et al (2007) Pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: a series of 126 patients. Medicine (Baltimore) 86:1–17
Lesca G, Olivieri C, Burnichon N et al (2007) Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. Genet Med 9:14–22
Todo K, Moriwaki H, Higashi M, Kimura K, Naritomi H (2004) A small pulmonary arteriovenous malformation as a cause of recurrent brain embolism. Am J Neuroradiol 25:428–430
White RI Jr, Lynch-Nyhan A, Terry P et al (1988) Pulmonary arteriovenous malformations: techniques and long-term outcome of embolotherapy. Radiology 169:663–669
Remy J, Remy-Jardin M, Wattinne L, Deffontaines C (1992) Pulmonary arteriovenous malformations: evaluation with CT of the chest before and after treatment. Radiology 182:809–816
Khalil A, Farres MT, Mangiapan G, Tassart M, Bigot JM, Carette MF (2000) Pulmonary arteriovenous malformations. Chest 117:1399–1403
Remy-Jardin M, Dumont P, Brillet PY, Dupuis P, Duhamel A, Remy J (2006) Pulmonary arteriovenous malformations treated with embolotherapy: helical CT evaluation of long-term effectiveness after 2–21-year follow-up. Radiology 239:576–585
Prasad V, Chan RP, Faughnan ME (2004) Embolotherapy of pulmonary arteriovenous malformations: efficacy of platinum versus stainless steel coils. J Vasc Interv Radiol 15:153–160
Milic A, Chan RP, Cohen JH, Faughnan ME (2005) Reperfusion of pulmonary arteriovenous malformations after embolotherapy. J Vasc Interv Radiol 16:1675–1683
Brillet PY, Dumont P, Bouaziz N et al (2007) Pulmonary arteriovenous malformation treated with embolotherapy: systemic collateral supply at multidetector CT angiography after 2–20-year follow-up. Radiology 242:267–276
Buscarini E, Danesino C, Olivieri C, Lupinacci G, Zambelli A (2005) Liver involvement in hereditary haemorrhagic telangiectasia or Rendu-Osler-Weber disease. Dig Liver Dis 37:635–645
Rodesch G, Hurth M, Alvarez H, Tadie M, Lasjaunias P (2002) Classification of spinal cord arteriovenous shunts: proposal for a reappraisal—the Bicetre experience with 155 consecutive patients treated between 1981 and 1999. Neurosurgery 51:374–379; discussion 379–380
Putman CM, Chaloupka JC, Fulbright RK, Awad IA, White RI Jr, Fayad PB (1996) Exceptional multiplicity of cerebral arteriovenous malformations associated with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome). Am J Neuroradiol 17:1733–1742
Maher CO, Piepgras DG, Brown RD Jr, Friedman JA, Pollock BE (2001) Cerebrovascular manifestations in 321 cases of hereditary hemorrhagic telangiectasia. Stroke 32:877–882
Maarouf M, Runge M, Kocher M, Zahringer M, Treuer H, Sturm V (2004) Radiosurgery for cerebral arteriovenous malformations in hereditary hemorrhagic telangiectasia. Neurology 63:367–369
Carette MF, Brugieres P, Khalil A (2007) Hyperintense basal ganglia on T1-weighted images in Rendu-Osler-Weber disease. Presse Med 36:883–884
Scelzo C, Greco S, Bonanni L et al (2007) The role of liver transplantation in the treatment of hereditary hemorrhagic telangiectasia: a short literature review. Transplant Proc 39:2045–2047
Caselitz M, Bahr MJ, Bleck JS et al (2003) Sonographic criteria for the diagnosis of hepatic involvement in hereditary hemorrhagic telangiectasia (HHT). Hepatology 37:1139–1146
Siddiki H, Doherty MG, Fletcher JG et al (2008) Abdominal findings in hereditary hemorrhagic telangiectasia: pictorial essay on 2D and 3D findings with isotropic multiphase CT. Radiographics 28:171–184
Garcia-Tsao G (2007) Liver involvement in hereditary hemorrhagic telangiectasia (HHT). J Hepatol 46:499–507
Longacre AV, Gross CP, Gallitelli M, Henderson KJ, White RI Jr, Proctor DD (2003) Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 98:59–65
Open Access
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License ( https://creativecommons.org/licenses/by-nc/2.0 ), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Carette, MF., Nedelcu, C., Tassart, M. et al. Imaging of Hereditary Hemorrhagic Telangiectasia. Cardiovasc Intervent Radiol 32, 745–757 (2009). https://doi.org/10.1007/s00270-008-9344-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00270-008-9344-2